Polypid Ltd. (PYPD) — SEC Filings
Polypid Ltd. (PYPD) — 46 SEC filings. Latest: 3 (Apr 6, 2026). Includes 36 6-K, 4 SC 13G/A, 3 SC 13G.
View Polypid Ltd. on SEC EDGAR
Overview
Polypid Ltd. (PYPD) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 3 filed on Apr 6, 2026: On March 18, 2026, Robert Benjamin Stein filed an initial statement of beneficial ownership of securities for PolyPid Ltd. The filing, designated as Form 3, indicates a change in ownership for the company's securities. The specific details of the ownership change, including the number of shares and
Sentiment Summary
Across 46 filings, the sentiment breakdown is: 4 bullish, 2 bearish, 40 neutral. The dominant filing sentiment for Polypid Ltd. is neutral.
Filing Type Overview
Polypid Ltd. (PYPD) has filed 1 3, 36 6-K, 2 20-F, 4 SC 13G/A, 3 SC 13G with the SEC between Jan 2024 to Apr 2026.
Filings by Year
Recent SEC Filings (46)
Risk Profile
Risk Assessment: Of PYPD's 36 recent filings, 1 were flagged as high-risk, 21 as medium-risk, and 14 as low-risk. The overall risk profile suggests moderate risk with a balanced mix of positive and cautionary disclosures.
Key Executives
- Robert Benjamin Stein
- 0001597158
- Brooke Story
- Nir Dror
- Jacob Harel
- Dr. Nurit Tweezer-Zaks
- Dikla Czaczkes Akselbrad
- Yitzchak Jacobovitz
Industry Context
PolyPid Ltd. operates in the biotechnology and pharmaceutical sector, focusing on the development of novel drug delivery technologies.
Top Tags
clinical-trial (6) · shareholder-meeting (5) · corporate-governance (5) · biotech (5) · medical-devices (4) · financial-results (4) · corporate-update (4) · financing (4) · phase-3 (3) · proxy-statement (3)
Key Numbers
| Metric | Value | Context |
|---|---|---|
| Patients | 400 | Number of patients expected to be enrolled in the Phase 3 trial |
| New Offering Size | $15.0M | Increased from $8.25M under the Sales Agreement with Oppenheimer & Co. Inc. |
| Previous Offering Size | $8.25M | The initial maximum aggregate offering price before the increase. |
| Warrants | 2,190,121 | Number of January 2024 Warrants subject to inducement offer. |
| Exercise Price | $5.50 | Price per Ordinary Share for the January 2024 Warrants. |
| Share Increase | 1,200,000 | Additional shares added to the Share Option Plan. |
| Total Reserved Shares | 3,512,403 | New aggregate number of shares available under the Share Option Plan. |
| Minimum Stockholders' Equity | $2.5M | Required by Nasdaq for continued listing on the Capital Market. |
| Reported Stockholders' Equity | $2.2M | PolyPid's equity as of September 30, 2024, below the Nasdaq requirement. |
| Shares/Warrants Issued | 4,493,830 | Represents the total number of securities to be sold in the private placement. |
| Compliance Period | 180 days | The timeframe PolyPid has to regain compliance with Nasdaq's minimum stockholders' equity requirement. |
| Share Offering Capacity | $8.25M | Maximum amount PolyPid can raise through the sale of ordinary shares. |
| Gross Proceeds | $3.8M | Capital raised from the private placement financing. |
| Shares/Warrants | 2,235,457 | Number of securities to be sold in the private placement. |
| Purchase Price | $1.70 | Price per share or warrant in the private placement. |
Related Companies
BDX · MYO · NASDAQ:POLY
Frequently Asked Questions
What are the latest SEC filings for Polypid Ltd. (PYPD)?
Polypid Ltd. has 46 recent SEC filings from Jan 2024 to Apr 2026, including 36 6-K, 4 SC 13G/A, 3 SC 13G. Each filing includes an AI-generated plain-English summary.
What is the overall sentiment of PYPD filings?
Across 46 filings, the sentiment breakdown is: 4 bullish, 2 bearish, 40 neutral. The dominant sentiment is neutral.
Where can I find Polypid Ltd. SEC filings explained simply?
ReadTheFiling provides AI-powered plain-English summaries of all Polypid Ltd. (PYPD) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and insider trades.
What are the key financial highlights for Polypid Ltd.?
Financial highlights for Polypid Ltd. are available when 10-K or 10-Q filings are enriched with AI analysis. Check back as new filings are processed.
What is the investment thesis for PYPD?
The investment thesis for PYPD includes bull, base, and bear case scenarios derived from AI analysis of recent SEC filings.
Who are the key executives at Polypid Ltd.?
Key executives identified across Polypid Ltd.'s filings include Robert Benjamin Stein, 0001597158, Brooke Story, Nir Dror, Jacob Harel and 3 others.
What are the main risk factors for Polypid Ltd. stock?
Of PYPD's 36 assessed filings, 1 were flagged high-risk, 21 medium-risk, and 14 low-risk.
What are recent predictions and forward guidance from Polypid Ltd.?
Forward guidance and predictions for Polypid Ltd. are extracted from SEC filings as they are enriched.